{"name": "Anchor Therapeutics",
 "permalink": "anchor-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/anchor-therapeutics",
 "homepage_url": "http://www.anchortx.com/",
 "blog_url": "",
 "blog_feed_url": "http://www.anchortx.com/news-events/press-releases.php",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@anchortx.com",
 "phone_number": "617-715-1999",
 "description": "",
 "created_at": "Sat Aug 21 01:49:41 UTC 2010",
 "updated_at": "Thu May 23 21:34:47 UTC 2013",
 "overview": "\u003Cp\u003EAnchor Therapeutics, Inc., a discovery and pre-clinical development-stage biopharmaceutical company, develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain. The company develops Pepducin lipopeptide drug candidates, which are molecules that target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. Its Pepducin technology platform is used to develop lipopeptide allosteric modulators for intractable GPCR targets. The company was formerly known as Ascent Therapeutics, Inc. and changed its name to Anchor Therapeutics, Inc. in March 2010. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       43],
      "assets/images/resized/0009/8740/98740v1-max-150x150.jpg"],
     [[250,
       73],
      "assets/images/resized/0009/8740/98740v1-max-250x250.jpg"],
     [[400,
       117],
      "assets/images/resized/0009/8740/98740v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Frederick",
      "last_name": "Jones",
      "permalink": "frederick-jones",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer",
    "person":
     {"first_name": "Stephen",
      "last_name": "Hunt",
      "permalink": "stephen-hunt",
      "image": null}},
   {"is_past": false,
    "title": "Acting President, and Senior Vice President, Preclinical R\u0026D",
    "person":
     {"first_name": "Thomas",
      "last_name": "McMurry",
      "permalink": "thomas-mcmurry",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/6179/266179v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6179/266179v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6179/266179v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Jochen",
      "last_name": "Knolle",
      "permalink": "jochen-knolle",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Thomas",
      "last_name": "Sakmar",
      "permalink": "thomas-sakmar",
      "image": null}},
   {"is_past": false,
    "title": "Board Of Directors",
    "person":
     {"first_name": "Cynthia",
      "last_name": "Lavoie",
      "permalink": "cynthia-lavoie",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/6174/266174v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6174/266174v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6174/266174v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Board Of Directors",
    "person":
     {"first_name": "Micahel",
      "last_name": "J.Berendt",
      "permalink": "micahel-j-berendt",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$10M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.anchortx.com/news-events/pr-AnchorSecures10MillionSeriesB082010.php",
    "source_description": "Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 8,
    "funded_day": 20,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "TVM Capital",
         "permalink": "tvm-capital",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0003/0797/30797v1-max-150x150.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-250x250.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HealthCare Ventures",
         "permalink": "healthcare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/9268/49268v1-max-150x150.jpg"],
             [[250,
               34],
              "assets/images/resized/0004/9268/49268v1-max-250x250.jpg"],
             [[290,
               40],
              "assets/images/resized/0004/9268/49268v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Venture Fund",
         "permalink": "novartis-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/9083/59083v2-max-150x150.png"],
             [[250,
               117],
              "assets/images/resized/0005/9083/59083v2-max-250x250.png"],
             [[318,
               150],
              "assets/images/resized/0005/9083/59083v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "67 Rogers Street",
    "address2": "",
    "zip_code": "02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Anchor Therapeutics licensing deal to net up to $480M",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2010/09/06/daily21-Anchor-Therapeutics-licensing-deal-to-net-up-to-480M.html",
    "source_text": null,
    "source_description": "Anchor Therapeutics licensing deal to net up to $480M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Anchor Therapeutics",
      "permalink": "anchor-therapeutics"}},
   {"description": "Anchor Therapeutics, Ortho-McNeil Strike $480M Deal",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 10,
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29\u0026aid=DJFVLS0020100910e69a00003\u0026r=Rss\u0026s=DJFVLS",
    "source_text": "",
    "source_description": "Anchor Therapeutics, Ortho-McNeil Strike $480M Deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Anchor Therapeutics",
      "permalink": "anchor-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}